Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation

Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation

Abstract Background Coronary artery bypass graft (CABG) is generally used to treat complex coronary artery disease. Treatment success is affected by neointimal hyperplasia (NIH) of graft and anastomotic sites. Although sirolimus and rosuvastatin individually inhibit NIH progression, the efficacy of...

Full description

Bibliographic Details
Main Authors: Ji-yeon Ryu, Eui Hwa Jang, JiYong Lee, Jung-Hwan Kim, Young-Nam Youn
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Journal of Translational Medicine
Subjects:
Sirolimus
Rosuvastatin
Intimal hyperplasia
Inflammation
Network pharmacology
Online Access:https://doi.org/10.1186/s12967-024-04875-8

Internet

https://doi.org/10.1186/s12967-024-04875-8

Similar Items